Compare Stocks: XRTX, PSTV, INTS, and CALC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$1.71 -1.5%	$2.87	$1.62 ▼ $36.00	$11.58M	0.83	192,981 shs	14,557 shs
INTS Intensity Therapeutics	$3.87 -0.5%	$4.23	$3.51 ▼ $43.50	$12.62M	2.76	21,927 shs	10,575 shs
PSTV Plus Therapeutics	$1.87 -4.1%	$3.14	$2.90 ▼ $23.42	$12.87M	1.4	116,506 shs	86,041 shs
XRTX XORTX Therapeutics	$1.75 +1.7%	$2.09	$1.59 ▼ $7.05	$3.19M	0.75	510,040 shs	14,271 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	-2.79%	-11.68%	-40.82%	-57.35%	-88.88%
INTS Intensity Therapeutics	-5.12%	+0.26%	-20.45%	-5.01%	-38.25%
PSTV Plus Therapeutics	-3.94%	-4.41%	-34.12%	-53.57%	-80.70%
XRTX XORTX Therapeutics	+1.18%	+3.61%	-23.89%	-21.46%	-60.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALC CalciMedica	$1.71 -1.5%	$2.87	$1.62 ▼ $36.00	$11.58M	0.83	192,981 shs	14,557 shs
INTS Intensity Therapeutics	$3.87 -0.5%	$4.23	$3.51 ▼ $43.50	$12.62M	2.76	21,927 shs	10,575 shs
PSTV Plus Therapeutics	$1.87 -4.1%	$3.14	$2.90 ▼ $23.42	$12.87M	1.4	116,506 shs	86,041 shs
XRTX XORTX Therapeutics	$1.75 +1.7%	$2.09	$1.59 ▼ $7.05	$3.19M	0.75	510,040 shs	14,271 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALC CalciMedica	-2.79%	-11.68%	-40.82%	-57.35%	-88.88%
INTS Intensity Therapeutics	-5.12%	+0.26%	-20.45%	-5.01%	-38.25%
PSTV Plus Therapeutics	-3.94%	-4.41%	-34.12%	-53.57%	-80.70%
XRTX XORTX Therapeutics	+1.18%	+3.61%	-23.89%	-21.46%	-60.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALC CalciMedica	2.20	Hold	$50.00	2,965.60% Upside
INTS Intensity Therapeutics	2.80	Moderate Buy	$7.00	78.57% Upside
PSTV Plus Therapeutics	2.33	Hold	$51.75	2,667.38% Upside
XRTX XORTX Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XRTX, PSTV, INTS, and CALC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	XRTX XORTX Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/27/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	CALC CalciMedica	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/18/2026	INTS Intensity Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $7.00
8/13/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	CALC CalciMedica	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/11/2026	INTS Intensity Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/29/2026	CALC CalciMedica	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	CALC CalciMedica	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/21/2026	INTS Intensity Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	PSTV Plus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALC CalciMedica	N/A	N/A	N/A	N/A	($2.30) per share	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	$4.94 per share	N/A
PSTV Plus Therapeutics	N/A	N/A	N/A	N/A	$0.72 per share	N/A
XRTX XORTX Therapeutics	N/A	N/A	N/A	N/A	$1.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALC CalciMedica	-$29.56M	-$6.80	N/A	N/A	N/A	N/A	-863.40%	-155.24%	11/11/2026 (Estimated)
INTS Intensity Therapeutics	-$11.61M	-$3.57	N/A	N/A	N/A	N/A	-116.61%	-94.01%	11/5/2026 (Estimated)
PSTV Plus Therapeutics	-$22.39M	-$2.30	N/A	N/A	N/A	-230.24%	-198.48%	-73.13%	N/A
XRTX XORTX Therapeutics	-$2.66M	-$2.73	N/A	N/A	N/A	N/A	-137.85%	-108.16%	11/12/2026 (Estimated)

Latest XRTX, PSTV, INTS, and CALC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2026	Q2 2026	XRTX XORTX Therapeutics	N/A	-$1.05	N/A	-$1.05	N/A	N/A
8/13/2026	Q2 2026	PSTV Plus Therapeutics	-$0.88	-$1.31	-$0.43	-$1.31	$1.11 million	$0.41 million
8/11/2026	Q2 2026	CALC CalciMedica	-$1.4250	-$0.45	+$0.9750	-$2.25	N/A	N/A
8/11/2026	Q2 2026	INTS Intensity Therapeutics	-$0.8725	-$1.11	-$0.2375	-$1.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
INTS Intensity Therapeutics	N/A	N/A	N/A	N/A	N/A
PSTV Plus Therapeutics	N/A	N/A	N/A	N/A	N/A
XRTX XORTX Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALC CalciMedica	1.67	5.58	5.58
INTS Intensity Therapeutics	0.01	5.00	5.00
PSTV Plus Therapeutics	N/A	2.27	2.27
XRTX XORTX Therapeutics	N/A	3.58	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CALC CalciMedica	N/A
INTS Intensity Therapeutics	3.74%
PSTV Plus Therapeutics	3.28%
XRTX XORTX Therapeutics	0.23%

Insider Ownership

Company	Insider Ownership
CALC CalciMedica	28.25%
INTS Intensity Therapeutics	7.60%
PSTV Plus Therapeutics	2.50%
XRTX XORTX Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CALC CalciMedica	15	6.83 million	4.90 million	No Data
INTS Intensity Therapeutics	2,021	3.26 million	3.02 million	Not Optionable
PSTV Plus Therapeutics	20	6.88 million	6.71 million	Not Optionable
XRTX XORTX Therapeutics	N/A	1.82 million	1.69 million	Not Optionable

XRTX, PSTV, INTS, and CALC Headlines

Recent News About These Companies

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO(TM), Targeting USD$700M+ U.S. Gout Market Opportunity

September 19, 2026 | barrons.com

XORTX Therapeutics Shares Rise 12% On IND Submission Plan

September 19, 2026 | rttnews.com

XORT Targets FDA IND Filing For XRx-026 Gout Program; NDA Submission Planned Within A Year

September 18, 2026 | rttnews.com

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

September 18, 2026 | globenewswire.com

XORTX Therapeutics (NASDAQ:XRTX) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?

September 15, 2026 | americanbankingnews.com

XORTX Begins Clinical, Commercial Manufacturing Of XORLO For Gout Program; Shares Surge To 31%

September 11, 2026 | rttnews.com

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

September 10, 2026 | financialpost.comF

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

September 10, 2026 | globenewswire.com

XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile

September 8, 2026 | tipranks.com

XORTX Re-Engages Investor Relations Program

September 8, 2026 | financialpost.comF

XORTX Re-Engages Investor Relations Program

September 8, 2026 | globenewswire.com

XORTX Slips 10% As Investor Relations Program Is Terminated And Postponed

August 28, 2026 | rttnews.com

XORTX Announces Termination and Postponement of Investor Relations Program

August 28, 2026 | globenewswire.com

XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet

August 17, 2026 | tipranks.com

XORTX Therapeutics Inc.

August 11, 2026 | barrons.com

XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo

August 4, 2026 | tipranks.com

XORTX Therapeutics Inc. annonce la démission d'Anthony Giovinazzo de son poste d'administrateur

August 2, 2026 | zonebourse.comZ

XORTX Therapeutics Inc.: XORTX Announces Director Resignation

August 1, 2026 | finanznachrichten.de

XORTX Announces Director Resignation

July 31, 2026 | financialpost.comF

XORTX Announces Director Resignation

July 31, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

XRTX, PSTV, INTS, and CALC Company Descriptions

CalciMedica NASDAQ:CALC

$1.71 -0.03 (-1.49%)

As of 10:51 AM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Intensity Therapeutics NASDAQ:INTS

$3.87 -0.02 (-0.49%)

As of 10:48 AM Eastern

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Plus Therapeutics NASDAQ:PSTV

$1.87 -0.08 (-4.10%)

As of 09/24/2026

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

XORTX Therapeutics NASDAQ:XRTX

$1.75 +0.03 (+1.74%)

As of 10:45 AM Eastern

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XRTX, PSTV, INTS, and CALC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XRTX, PSTV, INTS, and CALC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XRTX, PSTV, INTS, and CALC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XRTX, PSTV, INTS, and CALC Company Descriptions

CalciMedica NASDAQ:CALC

Intensity Therapeutics NASDAQ:INTS

Plus Therapeutics NASDAQ:PSTV

XORTX Therapeutics NASDAQ:XRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XRTX, PSTV, INTS, and CALC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XRTX, PSTV, INTS, and CALC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XRTX, PSTV, INTS, and CALC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XRTX, PSTV, INTS, and CALC Company Descriptions

CalciMedica NASDAQ:CALC

Intensity Therapeutics NASDAQ:INTS

Plus Therapeutics NASDAQ:PSTV

XORTX Therapeutics NASDAQ:XRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools